Continuing Education Opportunities

ClotCare Online Resource does not offer continuing education credit. We do, however, provide information and links to continuing education opportunities that we feel may be of value to our users. We hope you find this list useful. If you know of a continuing education opportunity that you feel may be useful to other ClotCare users, please tell us about it. You may contact us at webmaster@clotcare.com. If you are specifically interested in anticoagulation training programs, check out our Training Programs page.

The University of Illinois at Chicago Office of Continuing Education and Meeting Services-Programs offers a number of continuing education opportunities relating to anticoagulation and antithrombotic therapy. To review current opportunities, go to http://www.pharmacyce.uic.edu/Public/Catalog/

Thrombosis-Consult.com has a Free CME section that lists a number of Thrombosis-related CME opportunities. These listings are located at http://thrombosis.freecme.com/gallcourses.php

ThrombosisClinic.com is a continuing medical education resource for health care professionals emphasizing the latest in emerging approaches in the diagnosis, treatment, and prevention of thrombosis. Visit http://www.ThrombosisClinic.com for more information.

HemostasisCME.org offers a number of continuing education opportunities relating to thrombosis. Visit http://www.hemostasiscme.org/
ActivitiesByTopic.asp?tpc=3&title=Coagulopathy for a list of current programs.

Additional CE Opportunities

• NPSG Strategies - Improve Safety of Anticoagulation Therapy - Goal 3E
• Thrombosis Summit 2008 - N. American Thrombosis Forum
• SECAPS 2008 - An Evidence-Based Approach to Antithrombotic Therapy
• New Insights Into Coagulation: Cancer
• Beginning Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis
• New Mexico Thrombosis Journal Club Dinner
• Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis

Programs no Longer Offering Credit

• Real World Best Practices for DVT Prophylaxis
• Challenges in Dosing Low Molecular Weight Heparin
• Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion

Improve the Safety of Anticoagulation Therapy - NPSG 3E
Audio Conference

Date: August 7, 2008, 12:00 PM ET - 1:00 PM ET

Join Michael P. Gulseth, Pharm. D., BCPS and Inside the Joint Commission for an audio conference, August 7 at 12:00 (ET), when he reveals strategies for systematic anticoagulation care in the inpatient setting, including how to develop, implement and maintain an anticoagulation management service so you can comply with National Patient Safety Goal 3E.

Learning objectives include:

• The elements that must be covered in anticoagulant policies and the resource implications for meeting NPSG 3E
• How to meet the most difficult requirements under this goal - such as Element of Performance 1, which requires that your program tailor care to the specific needs of each patient on anticoagulant therapy
• Expert strategies for avoiding common pitfalls such as assigning a committee to oversee your anticoagulation management program instead of an individual
• Tested tactics for meeting each of the implementation expectations and potential measures of success

For more information or to register, go to http://www.decisionhealth.com/conferences/A1563/home.html

Thrombosis Summit 2008 - N. American Thrombosis Forum

SECAPS 2008 - An Evidence-Based Approach to Antithrombotic Therapy

Date: October 10 and 11, 2008

Location:
Cool Springs Marriott Hotel
700 Cool Springs Blvd.
(Nashville) Franklin, Tennessee 37067
615-261-6100

Organizers: The Southeastern College of Anticoagulation Providers in conjunction with The University of Tennessee Health Science Center (UTHSC) Colleges of Pharmacy and Nursing

Program Description and Target Audience:
The goals of this program are to improve the care of patients receiving anticoagulation or antithrombotic therapy. By facilitating patient-care/provider communication, providing up-to-date education concerning anticoagulation/anti-thrombotic issues, and enhancing the practice expertise of a multidisciplinary group of participants our goal can be reached. The target audience includes nurses, nurse practitioners, pharmacists, and other care providers.

Registration:
Early Registration before July 31, 2008: $120
Registration August 1 to September 21, 2008: $130
Registration after September 21, 2008: $150
One day Registration: $90
Onsite Registration: $165
Registration for Students and Residents: $90

Click here to download the brochure and registration form

You also may enroll online at https://web.dii.utk.edu/pharmenroll/Entrance.aspx.

New Insights Into Coagulation: Cancer

Date: October 31, 2008
Place: University of Pennsylvania Medical Center
Organizers: CME Office of the University of Pennsylvania
Chair: Eleanor S. Pollak, MD
Guest speaker: Bruce Furie, MD
Building: BRB II/III Auditorium

Arterial and venous thromboses are frequent complications of cancer. Thromboses occur due to multiple different mechanisms including malignant cells, and pathobiological reactions to these cells. New and aggressive therapies themselves designed to treat cancer also may increase the risk of thrombosis. Hemorrhage and bleeding may also occur. This conference will describe and highlight some of the many complications of cancer associated with abnormal coagulation.

Additional details coming soon.

Beginning Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis

When: November 6, 2008

Where: Albuquerque, New Mexico

Description: A one-day course for physicians, nurses, and pharmacists who are newcomers to the field of anticoagulation. This introductory course covers clinical and operational aspects of care and will be helpful to providers putting together an anticoagulation clinic, or just entering this field of medicine. It is recommended as a prerequisite for the Advanced Preceptorship if you are new to the science of thrombosis. Registration fee also includes breakfast, lunch, and participation in the New Mexico Thrombosis Journal Club dinner meeting the evening of November 6, a Thrombosis Primer, and a useful course syllabus.

Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 7.25 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The beginning course is also designated for up to 7.25 contact hours for nurses and 0.725 CEUs for pharmacists.

Download brochure & registration form.

More Information: http://secure.lcfresearch.org/lcfhome/
ProductDetails.aspx?event_uno=381

New Mexico Thrombosis Journal Club Dinner

When: November 6, 2008

Where: Albuquerque, New Mexico

Description: An opportunity to discuss current research in the field of thrombosis with our faculty, national conference guests, and professionals from the region. The fee for this dinner is included in the fee for the Management of Anticoagulation Preceptorships, or may be purchased separately.

Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The journal club is also designated for up to 1.0 contact hour for nurses and 0.100 CEU for pharmacists.

Download brochure & registration form.

More Information: http://secure.lcfresearch.org/lcfhome/
ProductDetails.aspx?event_uno=374

Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis

When: November 7-8, 2008

Where: Albuquerque, New Mexico

Description: A highly acclaimed, 2-day, in-depth course for those practicing in, or those newly responsible for setting up, anticoagulation clinics. This course is limited to 50 registrants to ensure high interaction with our expert faculty. The registration fee includes participation in the New Mexico Thrombosis Journal Club on November 6, a reception on November 7, a clinic site tour, breakfast and lunch each day, a Thrombosis Primer, and useful course syllabus.

Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 15.25 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The advanced course is also designated for up to 15.25 contact hours for nurses and 1.525 CEUs for pharmacists.

Download brochure & registration form.

More Information: http://secure.lcfresearch.org/lcfhome/
ProductDetails.aspx?event_uno=364

Real World Best Practices for DVT Prophylaxis

CME Credit hours: 1.5 AMA PRA Category 1 credits

Release date: July 25, 2006
Available for credit through: July 25, 2007

Program Description

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. While unfractionated heparin (UFH) has been the standard treatment of VTE for many years, low-molecular-weight-heparins (LMWHs) are now commonly used as a therapeutic alternative. Effective prophylaxis and intervention are essential in minimizing VTE risk and reducing the incidence of life-threatening events. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.

Target Audience

This activity is intended for healthcare providers who treat DVT.

Educational Objectives

Upon completion of this educational activity participants will be able to:

• Discuss the management of patients with venous thromboembolism: Challenges and Opportunities
• Understand treatment and secondary prophylaxis in VTE
• Discuss treatment options for management of acute PE
• Understand the current issues and controversies in VTE treatment and prophylaxis
• Discuss the new and current treatment options for DVT by examining current data
• Identify special considerations for the medically ill or patients with comorbidities

Faculty

• Paul E. Marik, MD, FCCP, FCCM
• Arthur P. Wheeler, MD, FCCP
• Jamie E. Siegel, MD
• Sandra L. Kane-Gill, PharmD, MSc.

View Program

The program is available online at:
http://www.cmediscovery.com/dvt/index.html

Challenges in Dosing Low Molecular Weight Heparin

CME Credit hours: 1.0

Release date: November 15, 2005
Available for credit through: November 15, 2007

Program Description

Anticoagulants are used in a wide variety of patients, for both therapeutic purposes and as prophylaxis against thromboembolism. The efficacy of these agents has been well established in clinical trials.

Unfractionated heparin can be hard to use, it binds to plasma proteins, and so there is wide variation in its anticoagulant effect. Vigilant monitoring of the PTT is necessary. Heparin-induced thrombocytopenia occurs about 3% of the time and this can be a big problem when it occurs.

Low molecular weight heparins are produced by depolymerization of unfractionated heparin, rendering them smaller and thus more bioavailable. There is less binding to plasma proteins and less inactivation by platelet factor 4. Because of their more predicable effects, routine laboratory monitoring for dose adjustment is usually not required.

There are solid clinical trial data indicating that low molecular weight heparins can be used as an alternative to unfractionated heparins. This program’s intention is NOT to review those data. Instead, this program features a discussion between four experts in critical care medicine. The discussion addresses the challenges in dosing and monitoring patients at the extremes of body weight, patients with renal insufficiency, and critically ill patients with altered plasma volume.

Target Audience

This activity is intended for Cardiologists, Hematologists, Intensivists, Pharmacists and other healthcare professionals who treat patients with LMWH.

Educational Objectives

Upon completion of this activity, participants will be able to:

• Maximize safety and efficacy while reducing harm when dosing LMWH.
• Identify dosing considerations in special populations (i.e. critically ill, obese, renal impaired).
• Have a greater understanding of the pharmaco-economics surrounding LMWH.

Faculty

• Joseph F. Dasta, MSc., FCCM, FCCP
• Steven M. Hollenberg, MD
• Sandra L. Kane-Gill, PharmD., MSc.
• Arthur P. Wheeler, MD

View Program

The program is available online at:
http://www.arcmesa.org/lmwh/default.aspx

Cancer and Thromboembolism

Pharmion Corporation has provided ClotCare Online Resource with a publication written by Joseph A. Caprini, MD, MS, FACS, RVT. This case presentation and discussion is entitled Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion. If you are interested in receiving CME credit for reviewing this publication, simply complete the questions provided and follow the instructions that accompany them.

You will need Adobe Reader to view this document. You may download a free copy from Adobe's website at http://www.adobe.com/products/acrobat/readstep2.html.

Read Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion